BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

Nkarta (NKTX)NkartaEarnings

Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 Cash balance of $216.0 million on September 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029

Related news

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

REGNRegeneron Pharmaceuticals2026-10-30 10:30 EST

Regeneron Reports Third Quarter 2026 Financial and Operating Results

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-11-06 21:01 EST

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

NKTXNkarta2026-11-05 21:34 EST

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

NKTXNkarta2026-09-10 11:00 EST

Nkarta to Participate in September Investor Conferences

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Stock data

Close
1.57 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States